Crystalline Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Crystalline Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,918	Closed	-$365K	–	115
2024 Q2	$365K	Buy	+8,918	New	+$371K	0.35%	44

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Crystalline Management's CERE Position: Q3 2024 in Review

Crystalline Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 8,918 shares — an estimated $365K sold.

Crystalline Management first reported a position in CERE in Q2 2024 and held it in 1 quarter. The position peaked at $365K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Crystalline Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Crystalline Management sold 8,918 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $365K.
Crystalline Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
Crystalline Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $365K in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Crystalline Management's 13F filing for Q3 2024, filed 8 Nov 2024.